Kornimate/medical-research-clean huggingface dataset:
study on the optimal diagnosis and treatment strategy of major depressive disorder based on anhedonia

Conditions: Outpatients / Inpatients With Depression

Summary: this study is a multicenter clinical research and focuses on the exploring of optimal diagnosis and treatment strategies of mdd based on anhedonia.

major depressive disorder (mdd) is a heterogeneious psychiatric disorder with complex etiology and pathogenesis. the lack of objective criteria for diagnosis and the use of trial-and-error treatment strategy are the current challenge. anhedonia is the core symptom of mdd and the aberrant reward system and abnormal inflammatory immune may be the pathological mechanisms. previous evidence suggests anhedonia cannot be improved quickly and efficiently by taking the first-line antidepressants. this study focuses on exploring the optimal diagnosis and treatment strategy for mdd patients with anhedonia. based on the hypothesis of inflammatory-immune system，neurotransmitter abnormalities and aberrant reward system, this study aims to evaluate the efficacy and safety of the combinations of escitalopram and aripiprazole and/or omega-3 polyunsaturated fatty acids for mdd patients with anhedonia with a factorial design. moreover, the multidimensional data including the clinicopathological features, neuroimaging data (mri) and inflammatory cytokines will be used to establish the model of diagnosis and treatment strategy.

Eligibility criteria:
inclusion criteria: 1. major depressive disorder according to diagnostic and statistical manual of mental disorders (5th edition) (dsm-5); 2. age: 18-55 (including 18 and 55) 3. hamd-17≥18 4. dars ≤ 28 5. do not receive repetitive transcranial magnetic stimulation (rtms) or modified electroconvulsive therapy (mect) treatment in past six months. 6. sign the informed consent form voluntarily and agree to participate in all visits, examinations and treatment as required by the trial protocol. exclusion criteria: 1. patients who are diagnosed with major somatic diseases; 2. patients who meet dsm-5 diagnostic criteria for other mental disorders: personality disorder, mental retardation; drug and/or alcohol dependence; 3. patients with severe suicidal tendencies or suicidal behavior; 4. pregnant or lactating women; 5. patients with mri contraindications; 6. patients who are regarded as unsuitable by investigators for this clinical trial.

Keywords: major depressive disorder anhedonia inflammatory immune reward system optimal treatment neurotransmitter
safety and tolerability of wve-120102 in patients with huntington's disease

Conditions: Huntington's Disease

Summary: precision-hd2 is a phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (pk), and pharmacodynamics (pd) of single and multiple doses of wve-120102 in adult patients with early manifest huntington's disease (hd) who carry a targeted single nucleotide polymorphism (snp) rs362331 (snp2).


Eligibility criteria:
key inclusion criteria: * prescreened with targeted snp on the same allele as the pathogenic cag expansion * ambulatory, male or female patients aged ≥25 - ≤65 years * clinical diagnostic motor features of hd, defined as unified huntington's disease rating scale (uhdrs) diagnostic confidence score = 4 * early manifest hd, stage i or stage ii based on uhdrs total functional capacity scores ≥7 and ≤13 key exclusion criteria: * malignancy or received treatment for malignancy, other than treated basal cell or squamous cell carcinoma of the skin, within the previous 5 years * received investigational drug or implantable device in prior 3 months or investigational oligonucleotide in prior 6 months or 5 halflives of the oligonucleotide, whichever is longer * clinically significant medical condition, unstable psychiatric symptoms, substance abuse, or pregnancy * inability to undergo brain mri * bone, spine, bleeding, or other disorder that exposes the patient to risk of injury or unsuccessful lumbar puncture
pogejiuxin decoction combination of conventional western medicine for the treatment of heart failure with preserved ejection fraction

Conditions: Heart Failure, Diastolic (HFpEF)

Summary: the objective of this study is to investigate the potential of pogejiuxin decoction to enhance the efficacy and mitigate the adverse effects associated with conventional treatment in patients with heart failure and preserved ejection fraction(hfpef), thereby establishing a foundation for its clinical application in managing hfpef.

this study recruits patients with heart failure and preserved ejection fraction(hfpef), randomly assigning them to either the intervention group or the control group. the control group will receive the standard heart failure treatment protocol, while the intervention group will take pogejiuxin decoction orally in addition to the control group\&#39;s treatment. the study will compare the degree of symptom improvement, relevant auxiliary examination indicators, traditional chinese medicine syndrome scores, and adverse reaction differences between the two groups, providing a clinical basis for the further enhancement of hfpef treatment with the combination of pogejiuxin decoction and conventional therapy.

Eligibility criteria:
inclusion criteria: 1. inpatients with heart failure who meet the diagnostic criteria of china guidelines for the diagnosis and treatment of heart failure 2018 and have grade ii-iv heart function; 2. inpatients who meet the diagnostic criteria for heart failure in tcm internal medicine(2012 edition); 3. patients who meet the diagnostic criteria for hfpef by heart color ultrasound; 4. patients who sign informed consent and take the test voluntarily. exclusion criteria: 1. patients who do not meet the inclusion criteria. 2. patients with severe hepatic or renal impairment (alt/ast \&gt; 3 times the upper limit or serum creatinine levels \&gt; 265 umol/l or serum potassium \&gt; 5.5 mmol/l). 3. patients with severe cerebrovascular, hematological, neurological diseases, or malignant tumors that require special treatment during the study period and may affect the judgment of heart failure treatment efficacy. 4. patients with severe pneumonia, serious infections, or acute exacerbation of chronic obstructive pulmonary disease. 5. pregnant or nursing women. 6. patients with psychiatric abnormalities or unwilling to cooperate. 7. patients allergic to the components of pogejiuxin decoction. 8. patients undergoing coronary intervention, cardiac pacemaker implantation, placement of cardiac assist devices, or other treatments during the trial period.

Keywords: pogejiuxin decoction heart failure with preserved ejection fraction
zephyr valve registry (zevr)

Conditions: Emphysema

Summary: the purpose of this post-approval registry is to gather ongoing safety and effectiveness assessment of the zephyr valve treatment in a real-world setting.

the zephyr valve registry (zevr) is a multi-center, single-arm, prospective registry. the objective of this registry is to provide ongoing safety and effectiveness assessment of the zephyr valve treatment of patients with hyperinflation associated with severe emphysema, in regions of the lung that have little to no collateral ventilation. approximately 150 patients undergoing zephyr valve treatment in the commercial setting will be enrolled and followed out to 3 years. assessments will be conducted at 45-days, 6-months, 12-months, 24-months and 36-months post-procedure. the zephyr valve registry will be conducted at a minimum of 5, and a maximum of 10 clinical sites. subjects prescribed zephyr valve treatment for their emphysema will be consented and will be enrolled only after determination of little to no collateral ventilation between target and ipsilateral lobes. safety and effectiveness of the zephyr valve treatment will be evaluated post-treatment based on data collected out to 3 years after the treatment.

Eligibility criteria:
inclusion criteria: * subjects with severe emphysema considered appropriate for the procedure by the physician. * subjects who signed an informed consent form to allow data collection. exclusion criteria: • subjects determined to have collateral ventilation between the target(s) and ipsilateral lobe(s).

Keywords: emphysema endobronchial valve treatments pulmonary rehabilitation lung volume reduction
l-arginine therapy on endothelium-dependent vasodilation & mitochondrial metabolism in melas syndrome

Conditions: MELAS Syndrome

Summary: melas patients suffer from exercise intolerance, weakness, poor vision or blindness, poor growth, developmental delay, and deafness. they also have unique 'stroke-like' episodes (sles) which are not due to blockages of large or medium arteries. these 'strokes' are thought to be due to energy failure of very small brain blood vessels combined with energy failure in the mitochondria (cell battery) of the brain cells, especially in the back region of the brain in the vision centre. this leads to visual loss and paralysis. the overall goal of this study is to better understand the mechanism of these sles at the level of the brain cells and small blood vessels.

we will study a family of 3 siblings, each with different severities of melas, using safe, non-invasive tests. we will determine whether there is a decrease in the ability of small brain blood vessels to increase blood flow by dilating in response to certain stimuli such as increased blood carbon dioxide levels or in response to brain cell activation in the vision centre by visual stimuli. we will use a technique called bold-fmri which can detect changes in brain blood flow. as exercising muscle also depends on increased blood flow and mitochondrial energy, we will study different measures of aerobic energy metabolism in exercising muscle using cycle exercise testing and special phosphorus-magnetic resonance spectroscopy which measures the changes in the major chemicals of muscle energy metabolism. the dietary amino acid l-arginine is known to dilate blood vessels increasing blood flow and to decrease toxic free radicals that are generated by dysfunctional mitochondria. we will determine the effect of a single dose and a 6 week trial of oral l-arginine, on brain blood vessel reactivity, brain cell activation and muscle aerobic function to see how useful this would be in the treatment of these patients and other mitochondrial disorders which present with strokes.

Eligibility criteria:
inclusion criteria: experimental siblings with melas (a3243g) syndrome * 17-23 years * followed neurometabolic clinic at the hospital for sick children will be studied. * normal electrolytes, glucose, renal and liver functions \& no history of gastrointestinal, respiratory or cardiac problems. controls -aged 17-23- sex matched to the melas subjects exclusion criteria: controls * experience migraines * have a metabolic disorder * taking medications predisposing to lactic acidosis or vasodilatation * neuromuscular/neurologic condition * cardiac or pulmonary disease * visual abnormalities * hypertension, anemia and prothrombotic state. control subjects * contraindication for mri (pacemaker, ocular metal, claustrophobia, tattoos) will be excluded from the study.

Keywords: pediatric melas mechanism of action of l-arginine
comparative evaluation of the finder instrument and finder g6pd cartridge in adults and neonates

Conditions: G6PD; G6PD Deficiency

Summary: a prospective clinical study to compare the clinical performance of the finder™ instrument and the g6pd assay to an fda cleared instrument/reagent combination in adult and neonate populations.

a prospective clinical study to compare the clinical performance of the finder™ instrument and the g6pd assay to an fda cleared instrument/reagent combination in adult and neonate populations. neonate and adult subjects will be recruited from 3 clinical sites. neonate samples will be collected as heel prick unless an in dwelling line is already in place at which point a venous or arterial/umbilical sample will be collected. adult samples will be collected as venous/arterial samples and finger stick samples. samples will be tested at the point of care/near patient and in the clinical laboratory using the finder instrument and g6pd assay on a digital microfluidic platform. samples will also be sent to a third party clia laboratory for test using an fda 510(k) cleared instrument/reagent combination for g6pd.

Eligibility criteria:
inclusion criteria: * neonates aged \>35 gestational weeks or older. * adult subjects who are age 18 and older. * adult subjects who weigh at least 110 pounds. * all ethnicities. * male and female subjects. exclusion criteria: * adult subjects who weigh less than 110 pounds. * subjects with anemia for which an attending physician will not authorize a blood draw. * subjects who have received a blood transfusion. * subjects who are pregnant.

Keywords: g6pd neonate
effect of prevention education in caries formation in pediatric patients with leukemia

Conditions: Leukemia

Summary: this randomized pilot clinical trial studies how well preventive education works in decreasing caries formation in pediatric patients with leukemia. prevention education may have an effect on factors important in causing cavities in pediatric patients with leukemia.

patients treated for leukemia at virginia commonwealth university medical center in the department of pediatric hematology and oncology are currently receiving oral hygiene instruction at diagnosis. in this study, patients will be randomized into two groups at diagnosis: one receiving current prevention education and the other group receiving one-on-one prevention education and counseling with the physician and pediatric dental resident. physician and pediatric dental resident will use motivational interviewing informed techniques during counseling. a caries risk assessment will be performed for each patient at diagnosis. caries incidence, plaque scores, mutans streptococci levels, salivary flow rate, and salivary ph will be assessed at week one (diagnosis), week 16 or start of interim maintenance therapy whichever comes second, week 32 or beginning of maintenance therapy whichever is later for all patients enrolled in the study. data will be collected through a clinical intraoral examination and salivary sample. data collected will be used to assess the effect of increased prevention education on factors of importance in caries formation.

Eligibility criteria:
inclusion criteria: * pediatric patients who have been recently diagnosed with leukemia * patients will also predictably be in primary or mixed dentition * patients of virginia commonwealth university medical center pediatric hematology oncology clinic exclusion criteria: * full permanent dentition * primary language is not english * children in the custody of the state with no parent or legal guardian present to sign consent
healthy marriage and responsible fatherhood grant program with phoenix house of new york

Conditions: Relationship, Family; Substance Use; Parenting

Summary: the purpose of this study is to provide a process and outcome evaluation of the hmrf grant-funded connections program. phoenix houses of new york, inc. has been given a new grant to continue and refine its successful connections program which equips single and coupled participants with significant substance use disorders (sud) with the skills and knowledge needed to (1) create and/or sustain healthy relationships/marriages, (2) equip participants with the skills and knowledge to raise children in a functional and healthy environment, (3) improve their financial stability, job readiness and employability to improve economic self-sufficiency and responsibility, and (4) reduce relationship stress and strain on interactions between co-parents.

the process evaluation will focus on: * documenting project implementations and determining efficient replication methods for effective program components, * monitoring completion of overall program goals and objectives, and * allow for quality improvement during the five year grant cycle. the outcome evaluation which focuses on participant level impact will ask the following: * does participation in evidence-based relationship education improve healthy relationship skills for single or coupled enrollees? * does participation in partner education and support classes improve co-parenting relationship? * do participants have better attitudes toward their ability to manage money (i.e. savings, paying bills) after workshops in financial literacy and other money management services? * do participants have improved attitudes on their own employability after workshops targeted at job readiness? * does participation in job readiness preparation translate into improved employment prospects or readiness factors? (readiness factors may include increased family assets and economic status.) * does participation in family care management sessions improve marriage/relationship, child and family well-being? * does participation in parenting education improve parenting skills and attitudes toward parenting? does participation in parenting education improve commitment to parenting and children?

Eligibility criteria:
inclusion criteria: * adult phoenix house clients who are enrolled in connections evidence-based interventions exclusion criteria: * inability to provide informed consent
estimation of biomechanical aortic wall properties in healthy and aneurysmal aortas using novel imaging techniques

Conditions: Abdominal Aortic Aneurysm

Summary: the primary aim of this study is to establish the practicality of using two novel imaging modalities for the assessment of biomechanical properties of the aorta.

patients with abdominal aortic aneurysm, (aaa), will be identified within the vascular surgery practice. those patients who meet standard indications for surgery including symptomatic aaa, size \>5.0-5.5 cm, or rapidly enlarging \>0.5 cm per 6 months will have standard pre-operative work-up which includes magnetic resonance angiogram (mra) and echocardiogram (echo). these pre-operative studies will be modified for the study patients to include electrocardiogram(ecg)-gating (coupled with mr angiogram) and 2-dimensional speckle-tracking ultrasound of the abdominal aorta. patients in the study will be followed for 1 year. measurements will be analyzed for any relationship between aortic wall properties and clinical outcomes such as aneurysm growth, rupture risk or aortic dissection. this study will be comparing 3 groups of patients: no surgery (surveillance), open surgery, and endovascular aneurysm repair (evar).

Eligibility criteria:
inclusion criteria: * patients \>18 years of age with ability to provide informed consent. * patients with either symptomatic or asymptomatic aaa as defined by aortic diameter ≥ 1.5x normal diameter. * patients with non-aneurysmal aortas who require aortic contrast imaging or echocardiography for preoperative planning or other reason. exclusion criteria: * patients with contraindication to iv contrast such as allergy or severe kidney dysfunction. * patients who do not require contrast imaging or echocardiogram as part of their care plan. * terminally ill patients, and patients with estimated life expectancy of ≤ 6 months. * patients unable to tolerate magnetic resonance imaging.
chemotherapy in treating patients with recurrent or metastatic colorectal cancer

Conditions: Colorectal Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining more than one drug may kill more tumor cells. purpose: phase ii trial to study the effectiveness of trimetrexate glucuronate, fluorouracil, and leucovorin in treating patients with recurrent or metastatic colorectal cancer.

objectives: i. evaluate tumor response and duration, one-year progression-free survival, and one-year overall survival in patients with recurrent or metastatic colorectal carcinoma when treated with trimetrexate glucuronate, fluorouracil, and leucovorin calcium. outline: patients receive trimetrexate glucuronate (tmtx) iv over 1 hour on day 1. beginning 18 hours after the tmtx dosage, patients receive leucovorin calcium (cf) iv over 2 hours. immediately after the completion of the cf infusion, patients receive an iv bolus injection of fluorouracil (5-fu). beginning 4 hours after the 5-fu infusion, patients receive oral cf every 6 hours for 6 doses. treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity or as long as the disease remains inoperable. patients are followed every 3 months for 1 year, every 6 months for 3 years, and then annually thereafter. projected accrual: a total of 18-45 patients will be accrued for this study within 15 months.

Eligibility criteria:
disease characteristics: histologically confirmed colorectal carcinoma inoperable advanced recurrent or metastatic disease measurable disease outside previously irradiated area no cns metastases patient characteristics: age: 18 to 74 performance status: who 0-1 life expectancy: more than 12 weeks hematopoietic: wbc greater than 4,000/mm3 platelet count greater than 100,000/mm3 hepatic: bilirubin less than 1.25 times upper limit of normal (uln) sgot less than 1.25 times uln albumin greater than 3.5 g/dl renal: creatinine clearance greater than 70 ml/min cardiovascular: no history of congestive heart failure, myocardial infarction within the past 6 months, active ischemic heart disease, or uncontrolled hypertension other: no weight loss more than 10% in the last 2 months no other prior malignancy except curatively treated carcinoma in situ of the cervix or non-melanoma skin cancer no history of alcohol abuse no uncontrolled medical or psychiatric disease not pregnant or nursing fertile patients must use effective contraception prior concurrent therapy: biologic therapy: no concurrent filgrastim (g-csf) chemotherapy: no prior chemotherapy for advanced disease recovered from prior adjuvant therapy no other concurrent chemotherapy endocrine therapy: not specified radiotherapy: see disease characteristics no prior radiotherapy for advanced disease surgery: see disease characteristics other: no other concurrent therapy

Keywords: stage iv colon cancer stage iv rectal cancer recurrent colon cancer recurrent rectal cancer
smart phone addiction and elbow joint performance

Conditions: Elbow Joint Performance, Ms Strength, Proprioception and Elbow Functional Abilities

Summary: smart phone addiction negatively impacted the pain in the muscles of the neck, shoulder, elbow, and the hand. the negative impact of prolonged smartphone use has shown an association between smartphone addiction and musculoskeletal pain in different areas of the body. caution should be taken towards the safe implementation of smartphone use. the combination of repetitive movements, poor posture, and over-use of mobile phones for texting or playing games, without taking rest breaks, can cause injury to the nerves, muscles, and tendons in the fingers, hands, wrists, arms, elbows, shoulders, and neck, which if ignored, may lead to long-term damage. staying stationary for hours with the same hand and elbow movements while using mobile phones not only disrupts the posture of the individual but also causes inefficiency at work. thus, their prolonged use significantly affects the quality of life as well as the activities of daily life of the individual .no previous study has investigated the link between smartphone addiction and elbow joint performance, to the authors' knowledge. therefore, the primary purpose of this study will be to determine the relationship between smartphone addiction and elbow joint performance.


Eligibility criteria:
inclusion criteria: * this study will comprise healthy volunteers between the ages of 18 and 30 who needed to use a smart phone. * dominant side will be involved. * subjects who put in more than 4 hours per day using smartphone. * willing to give consent to participate in this study. exclusion criteria: * recent fracture in neck and upper limb * any traumatic injury to neck and upper limb prior 6 months * congenital abnormalities and severe surgical and neurological disorders. * pregnant females